现代医院
現代醫院
현대의원
MODERN HOSPITAL
2015年
4期
40-42
,共3页
李莉珊%董豪坚%李国文%罗文辉
李莉珊%董豪堅%李國文%囉文輝
리리산%동호견%리국문%라문휘
厄贝沙坦%高血压%心力衰竭%超敏反应蛋白%脑钠肽
阨貝沙坦%高血壓%心力衰竭%超敏反應蛋白%腦鈉肽
액패사탄%고혈압%심력쇠갈%초민반응단백%뇌납태
Urban bei sha Tanzania%High blood pressure%Heart failure%Allergic reactions protein%Brain natriuretic pep-tide
目的:研究厄贝沙坦治疗高血压合并心力衰竭对超敏反应蛋白(hs -CRP)及脑钠肽(BNP)的影响。方法将我院124例患者抽签随机分为观察组与对照组,两组均为62例,两组均接受降血压等常规治疗;观察组同时口服厄贝沙坦治疗,比较两组临床疗效、BNP、hs -CRP、各体征指标及超声心电图检测结果差异。结果①两组治疗总有效率93.55% vs 80.65%,观察组显著较高(p <0.05);②治疗后观察组 BNP、hs-CRP 水平(104.62±22.84)mg/L、(4.68±1.51)mg/L ,比对照组(189.50±29.67)mg/L、(7.66±1.72)mg/L 显著较低(p <0.05);③治疗后观察组 LVDd、LVSd 分别为(54.61±4.28)、(40.62±6.17),显著低于对照组(62.61±6.33)、(53.10±7.31),LVEF、FS 分别为(49.27±7.44)、(42.30±7.18),显著高于对照组(42.30±7.18)、(16.87±5.06),比较差异有统计学意义(p <0.05);④两组不良反应发生率比较无显著差异(p >0.05)。结论厄贝沙坦治疗高血压合并心力衰竭可显著降低 BNP、hs -CRP 水平,且临床效果显著,可改善心功能,有临床应用价值。
目的:研究阨貝沙坦治療高血壓閤併心力衰竭對超敏反應蛋白(hs -CRP)及腦鈉肽(BNP)的影響。方法將我院124例患者抽籤隨機分為觀察組與對照組,兩組均為62例,兩組均接受降血壓等常規治療;觀察組同時口服阨貝沙坦治療,比較兩組臨床療效、BNP、hs -CRP、各體徵指標及超聲心電圖檢測結果差異。結果①兩組治療總有效率93.55% vs 80.65%,觀察組顯著較高(p <0.05);②治療後觀察組 BNP、hs-CRP 水平(104.62±22.84)mg/L、(4.68±1.51)mg/L ,比對照組(189.50±29.67)mg/L、(7.66±1.72)mg/L 顯著較低(p <0.05);③治療後觀察組 LVDd、LVSd 分彆為(54.61±4.28)、(40.62±6.17),顯著低于對照組(62.61±6.33)、(53.10±7.31),LVEF、FS 分彆為(49.27±7.44)、(42.30±7.18),顯著高于對照組(42.30±7.18)、(16.87±5.06),比較差異有統計學意義(p <0.05);④兩組不良反應髮生率比較無顯著差異(p >0.05)。結論阨貝沙坦治療高血壓閤併心力衰竭可顯著降低 BNP、hs -CRP 水平,且臨床效果顯著,可改善心功能,有臨床應用價值。
목적:연구액패사탄치료고혈압합병심력쇠갈대초민반응단백(hs -CRP)급뇌납태(BNP)적영향。방법장아원124례환자추첨수궤분위관찰조여대조조,량조균위62례,량조균접수강혈압등상규치료;관찰조동시구복액패사탄치료,비교량조림상료효、BNP、hs -CRP、각체정지표급초성심전도검측결과차이。결과①량조치료총유효솔93.55% vs 80.65%,관찰조현저교고(p <0.05);②치료후관찰조 BNP、hs-CRP 수평(104.62±22.84)mg/L、(4.68±1.51)mg/L ,비대조조(189.50±29.67)mg/L、(7.66±1.72)mg/L 현저교저(p <0.05);③치료후관찰조 LVDd、LVSd 분별위(54.61±4.28)、(40.62±6.17),현저저우대조조(62.61±6.33)、(53.10±7.31),LVEF、FS 분별위(49.27±7.44)、(42.30±7.18),현저고우대조조(42.30±7.18)、(16.87±5.06),비교차이유통계학의의(p <0.05);④량조불량반응발생솔비교무현저차이(p >0.05)。결론액패사탄치료고혈압합병심력쇠갈가현저강저 BNP、hs -CRP 수평,차림상효과현저,가개선심공능,유림상응용개치。
Objective To study the Irbesartan in treatment of hypertension with heart failure of hypersensitivity protein (hs-CRP) and the effect of brain natriuretic peptide (BNP).Methods 124 patients in our hospital were randomly divided into obser-vation group and control group with draw methods, 62 cases of each group.The two groups were accepted blood pressure and other conventional treatment; the observation group at the same time with irbesartan treatment.Two groups of clinical curative effect, the BNP, hs -CRP, various index signs and the ultrasonic cardiogram test Results were compared.Result ① two groups total effective 93.55% VS 80.65%, the observation group was significantly higher (p <0.05); ② the observation group after treatment the BNP, hs -CRP levels (104.62 ±22.84)mg /L、(4.68 ±1.51)mg /L was significantly lower (p <0.05), compared with the control group (189.50 ±29.67)mg /L、(7.66 ±1.72) mg /L; ③ Observation group after treatment LVDd, LVSd respectively (54.61 ±4.28), (40.62 ±6.17) was significantly lower than the control group (62.61 ± 6.33), (53.10 ±7.31), and LVEF, FS respectively (49.27 ±7.44), (42.30 ±7.18) was significantly higher than control group (42.30 ±7.18), (16.87 ±5.06) (p <0.05); ④ The incidence of adverse effects in two groups had no significant difference (p >0.05).Conclusion Irbesartan in treatment of hypertension with heart failure can significantly reduce the BNP and hs -CRP levels, improve heart function, and has high clinical value.